PARP inhibitor development for systemic cancer targeting.
about
Proteomic dissection of cell type-specific H2AX-interacting protein complex associated with hepatocellular carcinomaPoly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerDNA-repair pathway inhibitors for the treatment of ovarian cancerDNA-repair pathway inhibitors for the treatment of ovarian cancerNew treatment option for ovarian cancer: PARP inhibitorsTrial watch - inhibiting PARP enzymes for anticancer therapyDNA repair targeted therapy: The past or future of cancer treatment?Choices have consequences: the nexus between DNA repair pathways and genomic instability in cancerUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicIdentification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1PARP inhibitor treatment in ovarian and breast cancerPARP inhibition: PARP1 and beyondPARP inhibitors: its role in treatment of cancer.Induction of homologous recombination following in utero exposure to DNA-damaging agents.Chromatin composition is changed by poly(ADP-ribosyl)ation during chromatin immunoprecipitation.Evolutionarily conserved genetic interactions with budding and fission yeast MutS identify orthologous relationships in mismatch repair-deficient cancer cells.Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaksA specific isoform of poly(ADP-ribose) glycohydrolase is targeted to the mitochondrial matrix by a N-terminal mitochondrial targeting sequence.Poly(ADP-ribose) polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1).Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigmsCoordination of DNA repair by NEIL1 and PARP-1: a possible link to agingRole of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.The cytotoxic T lymphocyte protease granzyme A cleaves and inactivates poly(adenosine 5'-diphosphate-ribose) polymerase-1.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.The Hox genes and their roles in oncogenesis.AIF-independent parthanatos in the pathogenesis of dry age-related macular degeneration.A review of PARP inhibitors: from bench to bedside.Synthetic lethal approaches to breast cancer therapy.Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.Molecular simulations of drug-receptor complexes in anticancer research.Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable LiabilityStructural Requirements of Some 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide Derivatives as Poly (ADP-Ribose) Polymerase (PARP) for the Treatment of Cancer: QSAR Approach.MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.E. coli expression of a soluble, active single-chain antibody variable fragment containing a nuclear localization signal.
P2860
Q22001505-8F927B5D-4CC5-4C75-AAA7-0ECCDB84C418Q24187899-51CDC48E-792C-4DE8-B9D3-0A8CF9D29CB1Q24234893-8922884F-AD44-45C9-9DC3-5D7DF40D4D73Q24240854-7B689B52-379D-45C8-9956-F30A1BC4130EQ26745614-663F0434-9350-49B0-AE62-1E69444509CFQ26745673-01C4FFFD-3BFD-446B-A82D-7B85536C9BD1Q26768679-0DAAC695-7B93-43EB-B290-1CCF33BF58F2Q28066464-8A4DC67B-729E-4C7B-9AE3-364DB2FC38E2Q28071541-9E3A21E6-6B94-4148-8F64-1F88771C502EQ28475552-5420B5CD-39BD-46AF-A894-44DB8B134ACAQ28741688-1ACA23FD-0DB3-430E-BCFC-7DDE6645698FQ29619617-7801172B-59C2-4913-8779-EC85DF97C4CCQ33579740-819DE6A6-AF0B-4C77-949D-F16DC47F9789Q33760865-7EF66CF7-221B-4D17-A89A-75817644C1BEQ34221240-FA579BDA-CB61-4298-8C2C-B1AE30A373ECQ34306599-CE21F2A4-CA28-4710-8D8B-798F3AE1D797Q34567095-DD747F6C-22D1-4139-86FC-1C127CB30921Q34977457-3788ADB1-6813-4D53-816A-F58E05695885Q35639790-2D73A39E-CED1-4764-A789-9C76A9BBC873Q35955906-BA5576D3-2AB7-4C2A-978F-24FCF8B1935EQ36455184-7CFE4085-8D6A-4A45-9624-D23927CC3114Q36734840-6B1B482D-5765-431E-9569-D12E9AC7BF09Q37295146-2D8C160C-BE8B-4FCB-88B3-8969C2F38643Q37607283-935D097D-D8B8-40E7-83AD-8C9445E1D396Q37722452-90C1F6FE-3145-4759-B76B-4D72D059BE02Q37744863-EC36D2E6-3E34-4EE1-B893-DB353DC23962Q37774151-FCF69E1B-4A74-43C9-8813-4C3DAD814639Q37801265-307777F2-100F-406C-9FA1-9558F4E8F820Q37869838-D8B6A015-E7BA-484E-B6C5-2252AC365ACBQ37870216-B409B4EC-285B-4D2A-B8A2-65934419DC7AQ37912812-6CB4E2FF-9C1E-41CF-8EBC-F23889104551Q37925127-F9C7A6DC-D8D2-4503-BD1B-6E7A7A709802Q38054133-AB015B4C-9687-4D24-BC59-37D0869D2E39Q38469746-0BDCEF6E-E199-4160-9107-4C158BBF3124Q38596368-DFEF2F7B-CD6D-4B1A-8917-086ACE2F6AD0Q38881168-85E61D4C-22E7-4D3B-8127-1171923F1554Q38943129-32179B83-1D96-4F55-8923-E2D4FCCA2601Q38981784-5EF21FCA-93EE-4A98-B9F0-61655AC0BCFDQ39681333-42A2BC6D-7EE8-4254-962B-B9EAB8CA109CQ41502781-E35570DB-BE92-4D18-B6F7-1189AA435573
P2860
PARP inhibitor development for systemic cancer targeting.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
PARP inhibitor development for systemic cancer targeting.
@en
type
label
PARP inhibitor development for systemic cancer targeting.
@en
prefLabel
PARP inhibitor development for systemic cancer targeting.
@en
P1476
PARP inhibitor development for systemic cancer targeting.
@en
P2093
Nicola Jane Curtin
Tomasz Zaremba
P304
P356
10.2174/187152007781668715
P577
2007-09-01T00:00:00Z